WEC
ADPT icon

Winslow Evans & Crocker’s Adaptive Biotechnologies ADPT Stock Holding History

Winslow Evans & Crocker’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$12K Buy
200
+35
+21% +$1.8K ﹤0.01% 907
2020
Q3 		$8K Hold
165
– – ﹤0.01% 788
2020
Q2 		$8K Sell
165
-1
-0.6% -$36 ﹤0.01% 775
2020
Q1 		$6K Buy
166
+46
+38% +$1.28K ﹤0.01% 788
2019
Q4 		$4K Hold
120
– – ﹤0.01% 969
2019
Q3 		$4K Buy
+120
New +$4.9K ﹤0.01% 961

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Winslow Evans & Crocker's ADPT Position: Q4 2020 in Review

Winslow Evans & Crocker increased its Adaptive Biotechnologies (ADPT) stake by 21% in Q4 2020, buying an estimated $1.8K and bringing the position to 200 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #907.

Winslow Evans & Crocker first reported a position in ADPT in Q3 2019 and has held it in 6 quarters since. 250 funds tracked by Wall St. Rank hold ADPT as of Q4 2020.

  • Winslow Evans & Crocker held 200 shares of Adaptive Biotechnologies worth $12K as of Q4 2020.
  • Winslow Evans & Crocker bought 35 Adaptive Biotechnologies shares in Q4 2020, an estimated $1.8K.
  • Adaptive Biotechnologies made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #907 holding.
  • Winslow Evans & Crocker first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 6 quarters since.
  • 250 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.